Lakefront Swings To Profit In 9-months, Plans Second €50 Mln Share Buyback
Lakefront Biotherapeutics NV (LKFT) reported a €13.93 million profit for the 9-month period, reversing last year's €461.26 million loss, driven by lower costs and financial gains. Revenue declined to €26.17 million, while R&D expenses fell to €82.50 million. The company announced a second €50 million share buyback and plans to present Phase 1b data for Gamgertamig at ASH 2026. LKFT stock is up 5.49% at $35.17.
How this was made
The 30-second read
Why it matters
The earnings beat and buyback signal a turnaround, but the revenue decline and reliance on financial income suggest caution.
Market read
The news provides a fresh earnings and capital‑return catalyst for LKFT, likely prompting short‑term buying pressure.
What to watch
The upcoming FDA orphan designation and Phase 1b data release could add further upside if data are positive.
Background
Lakefront Biotherapeutics NV, formerly Galapagos, focuses on autoimmune and inflammatory disease therapies. The company recently sold its cell‑therapy pipeline and is shifting to a dollar functional currency.
Ticker impact
Lakefront Biotherapeutics reported a 9‑month profit, completed a €50 M buyback and announced a second €50 M buyback program, providing fresh earnings and capital‑return news.
upward pressure as the market prices in the profit turnaround and additional buyback.
The company swung from a large loss to profit, added cash flow from financial income, and is returning capital, all of which are bullish catalysts.
Market effects
Improves sentiment for European biotech small‑caps, showing that cost cuts and financial gains can quickly reverse losses.
May lift other Brussels‑listed biotech stocks as investors reassess valuation multiples.
Limited; primarily affects Lakefront and its immediate peer group.
Counterpoint
The profit is driven largely by one‑off financial income and currency gains; underlying revenue remains weak, so the rally could be short‑lived.
Key entities
- companyLakefront Biotherapeutics NV
Biotech firm reporting 9‑month profit and buyback program.
- companyArmed Cell Therapeutics
Buyer of Lakefront's early‑stage cell‑therapy pipeline.
